EUDA Health Holdings Limited has filed a 2026 prospectus supplement for its existing at-the-market equity program, allowing it to sell ordinary shares with an aggregate offering price of up to $10,000,000 through Chardan Capital Markets as sales agent. The company states that no ordinary shares have been sold under this Sales Agreement to date.
The supplement highlights business risks, including uncertainty around plans to work with third parties to establish a longevity clinic in Shenzhen, China, for which no binding agreements or approvals currently exist. It also notes uncertainty around launching an integrated digital health and rewards platform and the future use of QB coin utility cryptocurrency, which is still in development by a third party. EUDA cautions that failure of these initiatives could materially and adversely affect its business and results of operations.
EUDA Health Holdings Limited reported that it has entered into a second amendment to its warrant agreement with Streeterville Capital, LLC. The amendment, dated January 13, 2026, reduces the warrant exercise price from US$4.00 per share to US$2.00 per share and lowers the minimum closing price required to trigger a forced exercise from US$6.00 to US$3.00. All other warrant terms remain unchanged.
EUDA’s Chief Executive Officer, Alfred Lim, described the change as a technical adjustment intended to align the warrant terms with current market conditions and preserve flexibility in the company’s capital structure, while emphasizing that it does not alter EUDA’s long-term strategy or operational priorities in preventive and longevity-focused healthcare.
EUDA Health Holdings Limited is updating its prospectus for up to 2,000,000 ordinary shares issuable under a convertible warrant, reflecting new terms agreed with Streeterville Capital.
The Second Warrant Amendment cuts the exercise price from $4.00 to $2.00 per share and lowers the Nasdaq price needed for a “Forced Exercise” from $6.00 to $3.00, while the warrant remains unexercised. The company warns it is more likely than not that a large number of shares could be issued to the investor for no additional consideration if cash exercises or Forced Exercise conditions are not met, which would dilute other holders.
Assuming full cash exercise, EUDA estimates net proceeds of about $4.1 million, with $2.2 million earmarked for marketing and the balance for general corporate purposes and potential acquisitions. The company discloses that as of June 30, 2025, the transaction would increase net tangible book value per share from $(0.11) to $0.01, while implying dilution of $1.99 per share to new investors at the $2.00 price.
EUDA Health Holdings Limited reports a second amendment to an existing investor warrant originally issued for 2,000,000 ordinary shares for an aggregate purchase price of $100,000. The exercise price, which had already been reduced from $6.00 to $4.00 per share, is now further reduced to $2.00 per share. The minimum Nasdaq closing price required to trigger a Forced Exercise is also lowered from $6.00 to $3.00, subject to conditions including a $1,500,000 cumulative trading volume over five consecutive trading days and the shares being free trading on Nasdaq. The company states that no property or cash consideration was given by the investor for this amendment and will file a new prospectus supplement under its existing Form F-3 registration to reflect the revised warrant terms.
EUDA Health Holdings Limited reported that its subsidiary EUDA Health Pte. Ltd. entered into a convertible loan agreement with Shenzhen Inno Immune Co., Ltd., a stem cell therapy developer in China. EUDA expects to invest up to RMB 6 million in two tranches, with an initial RMB 1 million and a second RMB 5 million, subject to due diligence, regulatory approvals and definitive agreements.
The funding will be used by Shenzhen Inno to upgrade its cGMP facility in Shenzhen into a production and innovation center for stem cell treatments, intended to serve as a core hub for EUDA’s China strategy. The loan note carries an expected 6% annual interest, payable semi-annually, and can be converted into an equity interest in Shenzhen Inno or redeemed with accrued interest, according to the final terms.
EUDA Health Holdings Limited reports that it has amended its warrant agreement with Streeterville Capital, originally covering a warrant exercisable into up to 2,000,000 newly issued ordinary shares for an aggregate purchase price of US$100,000. The warrant was issued on December 4, 2025 and may be exercised for cash for ninety days from that date, after which a cashless exercise mechanism grants one ordinary share for every ten outstanding warrant shares.
Under the amendment signed on December 16, 2025, the exercise price per share is reduced from US$6.00 to US$4.00, and the minimum closing price required to trigger a “Forced Exercise” is lowered from US$7.50 to US$6.00, while all other warrant terms remain unchanged.
EUDA Health Holdings Limited has filed a prospectus supplement to end its continuous offering of Convertible Promissory Notes and the Ordinary Shares issuable upon their conversion under a prior prospectus. The company had the ability to issue up to US$10,000,000 of Convertible Notes and previously registered up to 5,000,000 Ordinary Shares for issuance upon conversion; as of this supplement it has sold Convertible Notes with an aggregate principal amount of $1,000,000 and issued 692,729 Ordinary Shares to the investor upon conversion. No additional Convertible Notes will be sold and no further shares will be issued under that note program. Separately, EUDA maintains a shelf registration allowing it to offer up to $100,000,000 of ordinary shares, warrants, subscription rights, debt securities and units over time. The filing also highlights the $15.0 million share-based acquisition of CK Health, for which EUDA issued 8,571,428 shares and later recognized a $14,762,562 impairment on related intangible assets, and notes that a significant shareholder holds demand registration rights for the 8,571,428 shares.
EUDA Health Holdings Limited reports that the investor in its August 2025 convertible note has agreed to convert the remaining $162,500 balance of the note into 81,250 ordinary shares. This completes conversion of the initial $1,000,000 August Note, of which $837,500 had already been converted into 569,859 shares before September 19, 2025. In addition, the investor previously received 41,620 shares at a conversion price of $0.901 per share under related letter agreements. The company also states that it does not intend to send any further put requests for additional notes under the original up to $10,000,000 purchase agreement.
EUDA Health Holdings announced a board change. Independent director Prof. Wong Kong Yew resigned effective October 23, 2025, including his roles as Chairman of the Compensation Committee and member of the Audit and Nomination Committees. The company stated his resignation was not due to any disagreement or dispute with the company or its Board.
On October 24, 2025, the Board appointed Huang Bo as an independent director, Chairman of the Compensation Committee, and member of the Audit and Nomination Committees. The Board determined Mr. Huang is independent under Nasdaq rules and Rule 10A-3. It reviewed his role at entities linked to a EUDA business partner and concluded this would not interfere with his independent judgment. The company also noted there are no related-party transactions involving Mr. Huang requiring disclosure.